Case report

Irvine-Gass syndrome after cataract surgery resolved by topical therapy with bromfenac eyedrops

Saviano, Bernardo Massimo MD*; Crisci, Erika MD; Viola, Giovanna MD; Gentile, Rodolfo MD; Gentile, Stefano MD; Di Staso, Silvio MD

Author Information
Journal of Cataract and Refractive Surgery Online Case Reports: January 2014 - Volume 2 - Issue 1 - p e1-e4
doi: 10.1016/j.jcro.2013.11.001
  • Free

Abstract

Irvine-Gass syndrome, first described by Irvine in 1953,1 is a condition in which cystoid macular edema (CME) develops in a patient after cataract surgery. Irvine-Gass syndrome is recognized as one of the most common causes of poor visual outcome following cataract surgery. It is thought that cataract surgical procedures cause a rapid increase in the intraocular levels of proinflammatory mediators (mainly prostaglandins); because of the blood–retinal barrier breakdown, these can spread toward the posterior pole. Although the number of CME cases after cataract surgery has declined over the past year, mainly due to the introduction of phacoemulsification and small-incision surgery, it is still recommended that a patient be evaluated before surgery to identify possible risk factors.2

The best way to diagnose and treat CME following cataract surgery is still debated; however, the ability to diagnose this disorder has improved, especially with the application of spectral-domain optical coherence tomography (OCT), a noncontact noninvasive reproducible investigation.3–8 Treatment options for Irvine-Gass syndrome include nonsteroidal antiinflammatory drugs (NSAIDs), corticosteroids, acetazolamide, and antivascular endothelial growth factor agents.9–14 We report a case of CME resolution and significant improvement of visual function following treatment with bromfenac topical therapy in a patient with Irvine-Gass syndrome.

CASE REPORT

On January 9, 2012, a 69-year-old white woman had cataract surgery in her right eye in our clinic. The surgery was conducted using phacoemulsification with a small-incision technique, stop-and-chop, and in-the-bag implantation of an intraocular lens (IOL). No complications occurred during surgery, and the standard treatment—tobramycin 0.3%–dexamethasone 0.1% 3 times daily for 7 days and diclofenac 0.9 mg/mL 3 times daily for 7 days and then twice daily for the next 21 days—was started postoperatively. At the first examination on January 16, 2012 (7 days after surgery), the patient had no apparent complications from the surgery; she was still receiving the standard therapy.

Sixteen days after the surgery, on January 25, 2012, the patient presented with a reduction in visual acuity, metamorphopsia, and a reduction in color perception. The OCT linear scans showed an increase in foveal thickness (857 μm). In the operated eye, the corrected distance visual acuity (CDVA) was 0.60 (logMAR) with +1.75 diopters (D) sphere; in the contralateral eye, it was 0.10 (logMAR) with 4.50 D sphere. The intraocular pressure (IOP) was 14 mm Hg in both eyes. Spectral-domain OCT showed an increase in retinal thickness, optically empty intraretinal spaces typical of CME, pigment epithelial detachments, a regular retinal profile with conservation of foveal depression, and diminished retinal reflectivity (Figure 1). At this time, standard therapy with 1.0 mg/mL diclofenac was discontinued and 0.9 mg/mL bromfenac eyedrops twice daily, 1 drop per eye, was initiated.

Figure 1.
Figure 1.:
Spectral-domain OCT scan of CME in the right eye at presentation 16 days after cataract surgery.

Five days after bromfenac was initiated (on January 30, 2012), the OCT showed a reduction in central foveal retinal thickness (205 μm) and optically empty intraretinal spaces (Figure 2). The CDVA was 0.10 (logMAR) with +0.50 D sphere in the right eye, and the IOP was 12 mm Hg in both eyes. The patient reported a subjective improvement in the metamorphopsia and color perception. Therapy with bromfenac was continued for another 14 days, with 2 drops administered to the eye twice daily.

Figure 2.
Figure 2.:
Spectral-domain OCT scan of the right eye 5 days after bromfenac was initiated.

At the follow-up examination on February 23, 2012, the central foveal retinal thickness was restored (203 μm) and the optically empty intraretinal spaces had disappeared on the OCT scan (Figure 3). The CDVA was 0.00 (logMAR) in the right eye, and the IOP remained 2 mm Hg in both eyes. The patient reported complete resolution of subjective visual symptoms.

Figure 3.
Figure 3.:
Spectral-domain OCT scan of the right eye at the follow-up examination approximately 1 month after initiation of bromfenac.

DISCUSSION

The underlying cause of CME after cataract surgery (Irvine-Gass syndrome) is unknown; however, various hypotheses have been proposed. One is that mechanical trauma from the surgery promotes the expression of cyclooxygenase (COX) at the mRNA and enzyme levels, which triggers the synthesis of various prostaglandins and other inflammatory mediators.15 These inflammatory mediators alter the blood–retinal barrier postoperatively, leading to increased permeability of perifoveal capillaries and fluid accumulation in the perifoveal retina.10,16 To prevent the development of CME after cataract surgery, NSAIDs have been shown to be effective in reducing the incidence of CME.10–13

Bromfenac is a NSAID that is marketed in Europe for the treatment of ocular inflammation and pain after cataract surgery,A although it is often prescribed in an off-label manner by physicians. Bromfenac inhibits the activity of COX, which in turn reduces the production of prostaglandins and inflammation. Bromfenac has a high degree of penetration through cell membranes, including ocular tissues, which can be attributed to the lipophilicity of the molecule.17,18,A This allows rapid, sustained drug levels of bromfenac in ocular tissues following drug administration. When administered as an ophthalmic solution, bromfenac has demonstrated significant efficacy at reducing inflammation in the eye following cataract surgery.19,20 Although the efficacy of bromfenac for the treatment of CME following cataract surgery is unknown, the efficacy of NSAIDs in cataract surgery has been shown and on this basis, it was decided to treat our patient with bromfenac eyedrops.

In this case of a 69-year-old white woman with CME following cataract surgery, bromfenac resolved CME with a reduction of central retinal thickness after 15 days of therapy, suggesting it is an effective and noninvasive treatment option in Irvine-Gass syndrome. To our knowledge, no other cases of bromfenac for the treatment of CME following cataract surgery have been reported; however, 1 prospective study investigating the prophylactic use of bromfenac in 62 patients after phacoemulsification and IOL implantation has been published.15 This study demonstrated that bromfenac suppressed anterior chamber inflammation and retinal thickening after cataract surgery, particularly in patients with diabetes. However, the study's sample size was relatively small and given that, the authors proposed further investigations to clarify the usefulness of bromfenac after cataract surgery. Another study investigated the addition of a topical NSAID (diclofenac, ketorolac, nepafenac, or bromfenac) to intravitreal corticosteroid treatment in patients with chronic pseudophakic CME.21 Similar to the results in our case, the study showed that adding bromfenac reduced retinal thickness in these patients. While the results of the case presented here support the findings of the previous studies of bromfenac for CME following cataract surgery, further studies investigating the effectiveness for the treatment of Irvine-Gass syndrome are warranted.

This case demonstrated that bromfenac resolved CME that developed following cataract surgery in an elderly white woman. Given this, we propose introducing it into standard therapy after cataract surgery to prevent retinal inflammation and edema.

REFERENCES

1. Irvine SR. A newly defined vitreous syndrome following cataract surgery; interpreted according to recent concepts of the structure of the vitreous; the Seventh Francis I. Proctor Lecture. Am J Ophthalmol 1953; 36:599-619.
2. Levin DS, Lim JI. Update on pseudophakic cystoid macular edema treatment options. Ophthalmol Clin North Am 2002; 15(4):467-472.
3. Huang D, Swanson EA, Lin CP, Schuman JS, Stinson WG, Chang W, Hee MR, Flotte T, Gregory K, Puliafito CA, Fujimoto JG. Optical coherence tomography. Science 1991; 254:1178-1181.
4. Hee MR, Puliafito CA, Wong C, Duker JS, Reichel E, Rutledge B, Schuman JS, Swanson EA, Fujimoto JG. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995; 113:1019-1029.
5. Puliafito CA, Hee MR, Lin CP, Reichel E, Schuman JS, Duker JS, Izatt JA, Swanson EA, Fujimoto JG. Imaging of macular diseases with optical coherence tomography. Ophthalmology 1995; 102:217-229.
6. Sourdille P, Santiago P-Y. Optical coherence tomography of macular thickness after cataract surgery. J Cataract Refract Surg 1999; 25:256-261.
7. Ching H-Y, Wong AC, Wong C-C, Woo DC, Chan CW. Cystoid macular oedema and changes in retinal thickness after phacoemulsification with optical coherence tomography. Eye 2006; 20:297-303. Available at: http://www.nature.com/eye/journal/v20/n3/pdf/6701864a.pdf. Accessed November 5, 2013.
8. Torrón-Fernández-Blanco C, Ruiz-Moreno O, Ferrer-Novella E, Sánchez-Cano A, Honrubia-López FM. Pseudophakic cystoid macular edema. Assessment with optical coherence tomography. Arch Soc Esp Oftalmol 2006; 81:147-153. Available at: http://scielo.isciii.es/pdf/aseo/v81n3/en_original3.pdf. Accessed November 5, 2013.
9. Degenring RF, Vey S, Kamppeter B, Budde WM, Jonas JB, Sauder G. Effect of uncomplicated phacoemulsification on the central retina in diabetic and non-diabetic subjects. Graefes Arch Clin Exp Ophthalmol 2007; 245:18-23.
10. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I); a preliminary report. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1977; 203:81-88.
11. Miyake K, Masuda K, Shirato S, Oshika T, Eguchi K, Hoshi H, Majima Y, Kimura W, Hayashi F. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicentered prospective trial. Jpn J Ophthalmol 2000; 44:58-67.
12. Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery; the results of a meta-analysis. Ophthalmology 1998; 105:397-405.
13. Rho DS. Treatment of acute pseudophakic cystoid macular edema: diclofenac versus ketorolac. J Cataract Refract Surg 2003; 29:2378-2384.
14. Shelsta HN, Jampol LM. Pharmacologic therapy of pseudophakic cystoid macular edema; 2010 update. Retina 2011; 31:4-12.
15. Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol 2010; 88:896-900. Available at: http://onlinelibrary.wiley.com/doi/10.1111/j.1755-3768.2009.01582.x/pdf. Accessed November 5, 2013.
16. Miyake K, Ibaraki N. Prostaglandins and cystoid macular edema. Surv Ophthalmol 2002; 47(suppl 1):S203-S218.
17. Sancilio LF, Nolan JC, Wagner LE, Ward JW. The analgesic and anti-inflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung 1987; 37:513-519.
18. Walsh DA, Moran HW, Shamblee DA, Uwaydah IM, Welstead WJ Jr, Sancilio LF, Dannenburg WN. Anti-inflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylphenylacetic acid and analogues. J Med Chem 1984; 27:1379-1388.
19. Donnenfeld ED, Holland EJ, Stewart RH, Gow JA, Grillone LR; for the Bromfenac Ophthalmic Solution 0.09% (Xibrom) Study Group. Bromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammation. Ophthalmology 2007; 114:1653-1662.
20. Stewart RH, Grillone LR, Shiffman ML, Donnenfeld ED, Gow JA. The systemic safety of bromfenac ophthalmic solution 0.09%. J Ocul Pharmacol Ther 2007; 23:601-612.
21. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010; 30:260-266.

OTHER CITED MATERIAL

A. European Medicines Agency. Summary of Product Characteristics. Yellox 0.9 mg/mL eye drops, solution. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001198/WC500107575.pdf. Accessed November 5, 2013
© 2014 by Lippincott Williams & Wilkins, Inc.
Data is temporarily unavailable. Please try again soon.